Fortress Biotech (FBIO) Fundamental Analysis: Revenue, Earnings & Valuation

1.76 / 10

Underperform

Fundamental analysis rates FBIO as Underperform with a 1.8/10 score. Inventory turnover and cost‑of‑sales ratios are strong, but long‑term debt, weak revenue growth and low operating margins undermine financial health.

Analysis Checks(5/10)

Revenue-MV

Value-0.22

Score2/3

Weight30.76%

1M Return4.88%

Total operating revenue (YoY growth rate %)

Value10.88

Score1/3

Weight-1.90%

1M Return-0.38%

Inventory turnover ratio

Value1.18

Score3/3

Weight-4.76%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value46.52

Score2/3

Weight1.87%

1M Return0.36%

PB-ROE

Value-0.46

Score1/3

Weight39.19%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value0.96

Score1/3

Weight-3.26%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-5.62%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value10.88

Score1/3

Weight-1.49%

1M Return-0.30%

Cost of sales ratio (%)

Value32.82

Score3/3

Weight1.40%

1M Return0.26%

Asset-MV

Value-0.49

Score1/3

Weight43.81%

1M Return6.31%

Is FBIO fundamentally strong?

FBIO scores 1.76/10 on fundamentals and holds a Premium valuation at present. Backed by its -6.22% ROE, -52.03% net margin, -49.45 P/E ratio, 1.50 P/B ratio, and 97.40% earnings growth, these metrics solidify its Underperform investment rating.